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The objectives of this review are:
￿ To highlight that although CYP450’sa r eam a j o r
target for drug-drug interactions other mechanisms
need to be considered.
￿ To appreciate that important interactions also
occur due to a change in pH (gut) and inhibition of
non P450 enzymes (eg UGTs).
￿ To discuss the increasing importance of under-
standing transporter based interactions in the gut,
liver, kidney and blood brain barrier.
￿ To outline new data on clinically important drug-
drug interactions between antiretrovirals and
between antiretrovirals and other drugs.
￿ To discuss how to predict, manage and avoid drug-
drug interactions including an outline of on-line
resources available for this purpose.
Pharmacokinetic drug interaction studies performed
during the drug development process, or post-licensing
p r o v i d et h es u b s t a n t i v ed a t ab a s ef r o mw h i c hr e c o m -
mendations regarding the use of certain drug combina-
tions are made. However given the sheer number of
potential interactions extra p o l a t i o no nt h eb a s i so f
potential mechanism of interaction is also important.
Thus a foundational knowledge of drug disposition
(enzymes, transporters involved etc) is essential so that
in vitro data (is the drug a substrate; is the drug an inhi-
bitor of a particular enzyme or transporter) can be used
to underpin a clinical study or be the basis for an
informed decision re the potential for an interaction.
While the major focus in the HIV field has been on
CYP450 enzymes (for the obvious reason that many of
the drugs are extensively metabolised and/or are indu-
cers/inhibitors) there is a growing awareness of the key
role for other proteins – in particular UDP-glucuronyl-
transferases (UGTs) and transporters (ABC transporters
such as P-pg, MRP1,2,7; SLCO transporters such as
OATP1B1, OATP1B3, OATP1A2, OCT1,2, OAT1,2).
This is a rapidly emerging field and one which is going
to impact not only on our understanding of mechanisms
of drug-drug interactions but also on seeing the bigger
picture in relation to the role of pharmacogenetics in
inter-individual variability.
Unexpected interactions will continue to emerge and
will need to be managed.
Ultimately the key to management of patients on mul-
tiple drugs is clinical vigilance, access to adequate
resources to help inform (eg web based resources), uti-
lity of therapeutic drug monitoring where available and
close follow up of patients.
Recommended reading:
Dickinson L, Khoo S, Back D. Pharmacokinetics and
drug-drug interactions of antiretrovirals: An update.
Antiviral Res. 2009 Aug 7 (Epub ahead of print).
Published: 11 May 2010
doi:10.1186/1742-4690-7-S1-I10
Cite this article as: Back: Drug-drug interactions: it is not only CYP450’s
which matter. Retrovirology 2010 7(Suppl 1):I10.
University of Liverpool, Liverpool, UK
Back Retrovirology 2010, 7(Suppl 1):I10
http://www.retrovirology.com/content/7/S1/I10
© 2010 Back; licensee BioMed Central Ltd.